- Home
- NRT vs OTLK Comparison
NRT vs OTLK Comparison
Compare NRT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- OTLK
- Stock Information
- Founded
- NRT 1975
- OTLK 2010
- Country
- NRT United States
- OTLK United States
- Employees
- NRT N/A
- OTLK N/A
- Industry
- NRT Oil & Gas Production
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRT Energy
- OTLK Health Care
- Exchange
- NRT Nasdaq
- OTLK Nasdaq
- Market Cap
- NRT 46.4M
- OTLK 48.3M
- IPO Year
- NRT N/A
- OTLK 2016
- Fundamental
- Price
- NRT $5.17
- OTLK $0.99
- Analyst Decision
- NRT
- OTLK Buy
- Analyst Count
- NRT 0
- OTLK 5
- Target Price
- NRT N/A
- OTLK $8.50
- AVG Volume (30 Days)
- NRT 40.7K
- OTLK 7.9M
- Earning Date
- NRT 08-29-2025
- OTLK 08-14-2025
- Dividend Yield
- NRT 9.28%
- OTLK N/A
- EPS Growth
- NRT 24.05
- OTLK N/A
- EPS
- NRT 0.59
- OTLK N/A
- Revenue
- NRT $6,184,173.00
- OTLK $1,505,322.00
- Revenue This Year
- NRT N/A
- OTLK N/A
- Revenue Next Year
- NRT N/A
- OTLK $343.94
- P/E Ratio
- NRT $8.88
- OTLK N/A
- Revenue Growth
- NRT 18.55
- OTLK N/A
- 52 Week Low
- NRT $3.88
- OTLK $0.79
- 52 Week High
- NRT $5.75
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- NRT 47.79
- OTLK 35.54
- Support Level
- NRT $4.90
- OTLK $1.02
- Resistance Level
- NRT $5.39
- OTLK $1.19
- Average True Range (ATR)
- NRT 0.16
- OTLK 0.11
- MACD
- NRT 0.00
- OTLK -0.00
- Stochastic Oscillator
- NRT 55.10
- OTLK 46.09
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.